Pfizer Inc. (NYSE: PFE) beats Q2-2026 adjusted Non-GAAP EPS consensus of approx. $0.68 per share (August 4, 2026)
Hit
✦ AI-generated prediction
Published on 17. July 2026
·
Predicted for 4. August 2026
·
Based on: Historical Cycle
Pfizer reports Q2-2026 results on August 4, 2026; analyst consensus stands at adjusted Non-GAAP EPS of approx. $0.68 (-12.8% YoY, prior year $0.78). Pfizer has actively restructured its portfolio post-COVID revenue decline — the Seagen acquisition and further oncology assets are expected to increasingly contribute to earnings from 2026. In the last four quarters Pfizer beat EPS expectations three times. Positive catalysts: RSV vaccine recovery (Abrysvo), gradual Paxlovid revenue return in budget-adjusted markets, and cost-reduction program on track. No Polymarket/Kalshi market available for this event.
Data basis for this prediction
- Nasdaq/Pfizer IR: Q2-2026-Bericht 4. August 2026 vor Börseneröffnung bestätigt
- Yahoo Finance: Konsens Non-GAAP EPS PFE Q2 2026 ~0,68 USD (-12,8 % YoY, Stand Juli 2026)
- Pfizer IR: Beat-Bilanz letzte 4 Quartale – 3 von 4 Quartalen EPS-Konsens übertroffen
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Hit
Pfizer meldete am 4. August 2026 einen bereinigten Non-GAAP-EPS von 0,77 USD für Q2 2026 – ein klarer Beat gegenüber dem Analystenkonsens von ca. 0,68 USD (Zacks). Das entspricht einer Übertreffung um 9 Cent bzw. ~13 %. Treiber waren Wachstum bei Eliquis, Padcev, der Vyndaqel-Familie und Lorbrena (überwiegend Seagen-Assets), die COVID-19-Rückgänge mehr als kompensierten. Pfizer hat damit laut eigenen Angaben den EPS-Konsens in allen zehn der letzten zehn Quartale übertroffen. Quellen: Yahoo Finance / Zacks ('PFE Q2 Earnings Top, 2026 Sales View Tweaked'), Seeking Alpha ('Pfizer tops Q2 expectations'), CNBC Q2-2026-Bericht.
📈 Economy
✦ AI
The S&P 500 closed at 7,636.36 on 9 September 2026. Falling below 7,450 by month-end would require a 2.4% decline. Headwinds: Fed rate hike of 25bp on 16 September (CentralBank.Watch: 59% probability), August PPI above expectations (+5.4% YoY), Iran-Gulf risk premium. Stabilizing factors: hike largely priced in (Polymarket: 93% for zero 2026 cuts), Q2 earnings solid, no recession signals. Historically, a single 25bp September hike rarely causes a monthly decline above 2.5%.
📈 Economy
✦ AI
Polymarket shows a 53% probability for a 25 basis point hike as of September 10, 2026. US Core CPI August 2026 (release September 11) is expected by market consensus to be above 3.0% YoY. The ECB raised its deposit rate by 25 bps to 2.50% on September 10, 2026 – an inflation-fighting signal that provides cover for the Fed. Against a hike: a mild slowdown in US industrial output. CME FedWatch also shows ~53% probability for a hike.
📈 Economy
✦ AI
The DAX closed at 25,562 points on September 9, 2026. A gain of +1.7% is required by month-end. Headwinds: ECB rate hike to 2.50% (September 10), 53% FOMC hike probability (September 16), persistently high oil prices (~$101/barrel Brent) weigh on energy-intensive DAX heavyweights. Tailwinds: strong SAP cloud growth expected, robust US demand, EUR/USD at 1.1644 benefits exporters. Implied 30-day volatility (VDAX): ~16%, corresponding to a σ range of roughly ±5.5% by month-end — the 26,000 level falls within the central distribution.